Pamela L. Zeitlin, MD, MPhil, PhD

Special Interests

My main area of expertise is in translational research in cystic fibrosis with a focus on chloride channels, protein chaperones, F508del pathophysiology and protein rescue in CF. I also have a role in pediatric asthma research. I have conducted investigator- initiated trials of 4-phenylbutyrate as a corrector in CF, anti-inflammatories in CF, Adeno-associated Viral gene therapy in CF, and many others. I held the IND for 4-phenylbutyrate for CF and hold the INDs for digitoxin and glycerolphenylbutyrate in CF. I also am a basic science investigator working in the area of chloride channels, proteomics, and protein trafficking. My laboratory is a translational environment where graduate students, clinical fellows, postdoctoral fellows and faculty can work collaboratively to advance our fundamental knowledge about CF airways disease.     

Awards & Recognition

Board Certification

Professional Memberships

National Societies:
American Association for the Advancement of Science
American Thoracic Society (Associate) Chair, Pediatric Assembly (5/2007-5/2009)
American College of Chest Physicians (Fellow)
American Physiological Society

Local Societies:
Maryland Lung Association

National Scientific Committees:
Question Writing Committee, General Pediatrics, American Board of Pediatrics (2013-present)
Member, Lung Cellular and Molecular Immunology study section (2008-2012)
Gilead Sciences Research Scholars Program review committee (2011)
Member, CRRC, NCRR, GCRC study section (2003-2007)
Chair-Elect, Subboard of Pediatric Pulmonology, American Board of Pediatrics
Chair, Pediatric Program Subcommittee of the American Thoracic Society
Subboard of Pediatric Pulmonology, American Board of Pediatrics (1999 - 2005)
National Institutes of Health Medical Biochemistry Study Section (1996- 2000)
National Institutes of Health, Special Emphasis Panels, Program Project Reviews (1994-96)

International Scientific Committees:
American Thoracic Society Pediatric Planning Committee (2010-present)
American Thoracic Society Pediatric Program Committee Chair Elect (2007)
American Thoracic Society Program Review Committee (2004-05)
Canadian Cystic Fibrosis Foundation Scientific Review Committee (2000-2003)
American Thoracic Society Program Planning Committee (2002)

Local Scientific Committees:
Maryland Lung Association, Executive Committee (1998-2000)
Maryland Lung Association, awards and grant committee (1991-95)

Publications

Henry KR, Lee S, Walker D, Zeitlin PL. Direct interactions between ENaC gamma subunit and ClCN2 in cystic fibrosis epithelial cells. Physiol Rep. 2015 Jan 27;3(1). pii: e12264. doi: 10.14814/phy2.12264. Print 2015 Jan 1.

Mayer-Hamblett N, Rosenfeld M, Treggiari MM, Konstan MW, Retsch-Bogart G, Morgan W, Wagener J, Gibson RL, Khan U, Emerson J, Thompson V, Elkin EP, Ramsey BW; EPIC; ESCF Investigators (Zeitlin PL). Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis. Pediatr Pulmonol. 2013 Oct;48(10):943-53.

Kerem E, Konstan MW, De Boeck K, Accurso FJ, Sermet-Gaudelus I, Wilschanski M, Elborn JS, Melotti P, Bronsveld I, Fajac I, Malfroot A, Rosenbluth DB, Walker PA, McColley SA, Knoop C, Quattrucci S, Rietschel E, Zeitlin PL, Barth J, Elfring GL, Welch EM, Branstrom A, Spiegel RJ, Peltz SW, Ajayi T, Rowe SM; for the Cystic Fibrosis Ataluren Study Group. Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med. 2014 May 15. pii: S2213-2600(14)70100-6. In press.

Lee S, Henderson MJ, Schiffhauer E, Despanie J, Henry K, Kang PW, Walker D, McClure ML, Wilson L, Sorscher EJ, Zeitlin PL. Interference with ubiquitination in CFTR modifies stability of core glycosylated and cell surface pools. Mol Cell Biol. 2014 Apr 28. [Epub ahead of print] PMCID: PMC4097669.

Schiffhauer, E, Vij N, Kovbasnjuk, O, Kang PW, Walker D, Lee S, Zeitlin, PL. Dual activation of CFTR and CLCN2 by lubiprostone in murine nasal epithelial. Am J Physiol Lung Cell Mol Physiol 2013 Mar 1;304(5):L324-31.

Teaching & Professional Positions

Conflicts of Interest

National Jewish Health physicians and scientists may collaborate with pharmaceutical or other industries to develop medical and scientific breakthroughs or to provide education on trends in quality medical practice and outcomes to physicians and health professionals around the country. National Jewish Health maintains a strict conflict of interest policy to ensure that all potential conflicts are clearly visible and that management plans are put in place in order to further innovation and education while ensuring the protection of our patients and the integrity of our research. National Jewish Health publicly discloses any payment to our physicians or scientists. View this faculty member’s industry relationships and collaborations.